Jessica Camacho

Jessica Camacho

Auto-generated profile, based on publicly available information

Jessica Camacho

Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Cancer Research Communications
Verified
Journal Article
Open access
AZAlexander Zheleznyak
Alexander Zheleznyak
DDDhanusha Duraiyan
Dhanusha Duraiyan
PTPrasanth Thunuguntla
Prasanth Thunuguntla
JCJessica Camacho
Jessica Camacho
SWShuang Wu
Shuang Wu
CMChristopher Malone
Christopher Malone
Molecular signatures predict prognosis in hepatocellular carcinoma, but their relevance to transarterial radioembolization (TARE) with yttrium-90 (90Y) is unknown. We aimed to identify baseline and treatment-induced pathways associated with response and nominate biomarkers. Ten transcriptomically diverse human liver cancer cell lines were exposed to escalating activities of glass 90Y microspheres for 10 days. Normalized AUC values quantified sensitivity. Whole-transcriptome RNA sequencing at baseline and after treatment was analyzed with elastic net regression and gene set enrichment. Findings were corroborated by qRT-qPCR and exploratory analysis of pretreatment tumor samples from patients undergoing TARE. Liver cancer cell line responses to 90Y were heterogeneous, with resistance aligning to Hoshida S1 and cholangiocarcinoma-like subtypes. Epithelial–mesenchymal transition (EMT) and adhesion pathways were enriched in resistant lines, with CD44 and ITGA3/α3β1 emerging as candidate markers, corroborated by RNA and protein expression. After 90Y exposure, resistant lines upregulated IFNγ/α, TNFα/inflammatory, and antigen presentation–related pathways, whereas sensitive lines downregulated these pathways along with DNA repair and oxidative phosphorylation. In an exploratory patient cohort, higher tumor CD44 expression trended with early progression. In conclusion, liver cancer cell lines display marked biological heterogeneity in response to 90Y. Baseline EMT/adhesion signatures and stress response pathways nominate CD44 and ITGA3/α3β1 as candidate biomarkers of resistance. These findings delineate molecular programs of β-emitter radioresistance and identify candidate pathways for future targeting. Significance: TARE with 90Y is widely used for liver cancer, yet its molecular determinants of response are poorly understood. Using a diverse panel of liver cancer cell lines, we identify EMT, adhesion, and stress response pathways associated with resistance. These findings highlight candidate biomarkers and molecular vulnerabilities that may guide future therapeutic strategies and patient selection.

22 January 2026
Verified
Other
Open access
AZAlexander Zheleznyak
Alexander Zheleznyak
DDDhanusha Duraiyan
Dhanusha Duraiyan
PTPrasanth Thunuguntla
Prasanth Thunuguntla
JCJessica Camacho
Jessica Camacho
SWShuang Wu
Shuang Wu
CMChristopher Malone
Christopher Malone
Details of liver cancer cell lines

22 January 2026
Verified
Other
Open access
AZAlexander Zheleznyak
Alexander Zheleznyak
DDDhanusha Duraiyan
Dhanusha Duraiyan
PTPrasanth Thunuguntla
Prasanth Thunuguntla
JCJessica Camacho
Jessica Camacho
SWShuang Wu
Shuang Wu
CMChristopher Malone
Christopher Malone
Differential expression and GSEA after 90Y treatment in individual cell lines.

22 January 2026
Verified
Other
Open access
AZAlexander Zheleznyak
Alexander Zheleznyak
DDDhanusha Duraiyan
Dhanusha Duraiyan
PTPrasanth Thunuguntla
Prasanth Thunuguntla
JCJessica Camacho
Jessica Camacho
SWShuang Wu
Shuang Wu
CMChristopher Malone
Christopher Malone
Study rationale, design, and experimental workflow. Heterogeneity of response in a preliminary cohort of patients with HCC showing (A) cases of IR or OFP within 12 months of 90Y-RE vs. (B) sustained responders (SR), defined as no IR or OFP within 12 months of treatment. Each row indicates one patient, with panels from left to right demonstrating baseline contrast-enhanced MR (red arrows highlighting tumors of interest), immediate post-therapy 90Y SPECT/CT and treatment details, including reported dose, and follow-up MR at indicated time point showing outcomes. C, A panel of 10 human liver cell lines spanning the transcriptomic spectrum as demonstrated by PCA of baseline RNA expression profiles. D, Cells were treated at escalating activities of 90Y microspheres (0–20 MBq/mL) for 10 days in 24-well cell culture plates using 0.4-μm pore inserts to physically separate microspheres to enable removal for downstream assays. Cell viability (MTS) was measured in triplicate per condition across activity range. Baseline and posttreatment (20 MBq/mL) RNA-seq followed by differential expression analysis was performed in biological triplicates in selected (7) cell lines presenting a spectrum of sensitivity to 90Y microsphere treatment. * for multifocal BCLC A, only 1 tumor shown for illustrative purposes. BCLC, Barcelona Clinic Liver Cancer; EHS, extrahepatic spread; MCD, multicompartment dosimetry; MIRD, medical internal radiation dose; Pt, patient; RS, radiation segmentectomy.

22 January 2026
Verified
Other
Open access
AZAlexander Zheleznyak
Alexander Zheleznyak
DDDhanusha Duraiyan
Dhanusha Duraiyan
PTPrasanth Thunuguntla
Prasanth Thunuguntla
JCJessica Camacho
Jessica Camacho
SWShuang Wu
Shuang Wu
CMChristopher Malone
Christopher Malone
Overall abundance of key genes before and after 90Y treatment.

22 January 2026
Verified
Other
Open access
AZAlexander Zheleznyak
Alexander Zheleznyak
DDDhanusha Duraiyan
Dhanusha Duraiyan
PTPrasanth Thunuguntla
Prasanth Thunuguntla
JCJessica Camacho
Jessica Camacho
SWShuang Wu
Shuang Wu
CMChristopher Malone
Christopher Malone
Differential gene expression between 90Y-resistant and sensitive cell lines after 90Y microsphere treatment